# IMIDomics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/imidomics

- Industry: Biotechnology
- Headquarters: Barcelona, Spain
- Website: www.imidomics.com
- Total disclosed funding: $17M
- Latest round: Series A (Jul 27, 2021)
- Investors on record: 4

## About

Based in Spain, IMIDomics Inc. is a biopharmaceutical company dedicated to developing novel therapeutics targeting immune-mediated inflammatory diseases (IMIDs).Founded in 2015 and headquartered in Barcelona, Spain, IMIDomics Inc. focuses on innovative treatments for a range of IMIDs. The company recently raised USD 16.5 mn in a Series A funding round on July 27, 2021, led by DNS Capital, with participation from Bristol-Myers Squibb Company, Tao Capital Partners, and The Pritzker Organization. This investment aims to support precision discovery efforts and expand teams in the US and Europe.IMIDomics specializes in the development of first-in-class medicines aimed at treating immune-mediated inflammatory diseases (IMIDs) such as Systemic Lupus Erythematosus, Ulcerative Colitis, Crohn’s Disease, Rheumatoid Arthritis, Psoriasis, Psoriatic Arthritis, Atopic Dermatitis, and Sjögren’s Syndrome. The company’s innovative pipeline is supported by a proprietary database comprising over 17 years of clinical and biomolecular data, which aids in identifying the most suitable patient populations for each therapeutic candidate. IMIDomics focuses on creating targeted therapies that specifically address the needs of patients who do not adequately respond to existing treatments, thereby enhancing the effectiveness of care. The company serves a diverse clientele including healthcare providers, research institutions, and pharmaceutical partners across various regions, including the United States and Europe.IMIDomics generates revenue primarily through partnerships and collaborations in the pharmaceutical industry. The company engages in B2B transactions with pharmaceutical companies and healthcare providers, providing access to its extensive biobanking and data analytics capabilities. Revenue streams are derived from licensing agreements for its proprietary drug candidates and services related to patient data analysis. Through these collaborations, clients benefit from tailored therapeutics aimed at specific patient demographics, which allows for a more effective treatment regimen. The company emphasizes a patient-centric approach, which not only benefits the healthcare providers and pharmaceutical partners but also ultimately enhances patient outcomes in the treatment of IMIDs.Following the recent funding of USD 16.5 mn raised in July 2021, IMIDomics plans to accelerate its precision discovery efforts and enhance its technologies. The company aims to expand its operations further into the US and European markets, focusing on the development of new therapeutic candidates for IMIDs. Specific timelines for upcoming product launches have not been detailed, but the funding will support the expansion of teams and capabilities necessary to realize these goals.

## Funding rounds

- Series A, Jul 27, 2021, $17M — Bristol-Myers Squibb Company, The Pritzker Organization, DNS Capital, Tao Capital Partners

## Investors

- Bristol-Myers Squibb Company — Series A
- The Pritzker Organization — Series A
- DNS Capital (https://capitalatlas.ai/funds/dns-capital) — Series A
- Tao Capital Partners (https://capitalatlas.ai/funds/tao-capital-partners) — Series A